<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thromboembolic complications during pregnancy are the most common causes of maternal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we report on thromboembolic prophylaxis of 60 pregnancies of 32 pregnant women with familial <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Long-term Fraxiparine (Sanofi-Chinoin) as thromboprophylaxis was applied in 26 cases throughout pregnancy </plain></SENT>
<SENT sid="3" pm="."><plain>UFH (<z:chebi fb="5" ids="28304">Heparin</z:chebi>-Ca inj.) was used in 11 cases, and there were 23 pregnancies without thromboembolic prophylaxis in our patient's case histories </plain></SENT>
<SENT sid="4" pm="."><plain>Artificial abortions were not included in this paper </plain></SENT>
<SENT sid="5" pm="."><plain>The ratio of successful pregnancies were: with Fraxiparine: 24/26 (92.3%), with UFH (<z:chebi fb="5" ids="28304">Heparin</z:chebi>-Ca): 8/11 (72.7%), without prophylaxis: 4/23 (17.4%) </plain></SENT>
<SENT sid="6" pm="."><plain>In the patient group treated with Fraxiparine there were no foetopathy, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> or <z:mp ids='MP_0001914'>bleeding</z:mp> complication </plain></SENT>
<SENT sid="7" pm="."><plain>LMWH is recommended for pregnant women with familial <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>According to literature data and our own experiences the doses of LMWH in patients with familial <z:hpo ids='HP_0100724'>thrombophilia</z:hpo>, and -<z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, and -artificial heart value are suggested </plain></SENT>
</text></document>